One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1136/jitc-2021-004226
Copy DOI
Export
Save
Share
Cite Journal: Journal for ImmunoTherapy of Cancer |  Publication Date: Jun 1, 2022 |
 Citations: 14 |  License type: open-access |
Affiliation: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Novartis (United States), Mount Vernon Cancer Centre, Institut Gustave Roussy, University of Paris-Saclay, Institut Polytechnique de Paris, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Heidelberg University, University Hospital Heidelberg, University Hospital of Zurich, Novartis (Switzerland), Tris Pharma (United States), Royal North Shore Hospital, Melanoma Institute Australia, University of Sydney, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital
BackgroundThe randomized phase 3 COMBI-i trial did not meet its primary endpoint of improved progression-free survival (PFS) with spartalizumab plus dabrafenib and trametinib (sparta-DabTram) vs placebo plus dabrafenib and trametinib...
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
